Search results for "registri"

showing 10 items of 634 documents

Incidence and outcome of cerebrovascular events related to cervical artery dissection: the Dijon Stroke Registry.

2013

Background Reliable epidemiological data on the true incidence of cerebrovascular events related to spontaneous cervical artery dissection, including stroke and transient ischemic attack, are scarce. Aims To evaluate the incidence, characteristics, and outcome of cerebrovascular events due to cervical artery dissection. Methods All cerebrovascular events (stroke and transient ischemic attack) occurring in Dijon, France, from 2006 to 2011, were retrieved from a population-based registry. Patients with a cervical artery dissection were identified. Incidence rates, baseline characteristics, and outcome at three-months were described. Results Among the 1368 patients with cerebrovascular events,…

MaleStroke registrymedicine.medical_specialtyCervical ArteryVertebral artery dissectionDissection (medical)Carotid Artery Internal DissectionInternal medicineEpidemiologymedicineHumansRegistriesStrokeAcute strokeVertebral Artery Dissectionbusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseStrokeNeurologyIschemic Attack TransientCardiologyFemaleRadiologyFrancebusinessInternational journal of stroke : official journal of the International Stroke Society
researchProduct

Temporal Trends in the Incidence of Ischemic Stroke in Young Adults: Dijon Stroke Registry

2021

<b><i>Introduction:</i></b> Stroke is associated with major consequences in terms of socioeconomic impact and lost disability-adjusted life in young victims, thus justifying a careful surveillance of epidemiological trends. This study aimed to assess changes in the incidence of ischemic stroke in young adults over a long period. <b><i>Methods:</i></b> All cases of first-ever ischemic stroke that occurred among adults aged 18–55 years were prospectively recorded using the population-based Dijon Stroke Registry, from 1985 to 2017. Sex-specific annual incidence rates were calculated and were presented according to 6 time periods. Incidence rate r…

MaleStroke registrymedicine.medical_specialtyPediatricsEpidemiologyPopulationBrain IschemiaYoung AdultLong periodEpidemiologymedicineHumansRegistriesYoung adulteducationStrokeIschemic Strokeeducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Middle Agedmedicine.diseaseStrokeIschemic strokeFemaleNeurology (clinical)businessNeuroepidemiology
researchProduct

Early Seizures After Acute Stroke: A Study of 1,640 Cases

1994

We evaluated prospectively the occurrence of seizures within 15 days of a first stroke or transient ischemic episode in 1,640 patients to study relation between seizures and type of stroke. Seizures occurred in 90 patients (5.4%), including 36 (4.4%) of 814 with infarct owing to atheroma, 21 (16.6%) of 126 with infarct owing to cardiogenic embolus, 3 (1%) of 273 owing to lacunar infarct, 5 (1.9%) of 259 owing to transient ischemic attack (TIA), 21 (16.2%) of 129 owing to supratentorial hematoma, and 4 (16.6%) of 24 owing to subarachnoid hemorrhage. Thirteen (14.6%) of 89 subcortical infarcts were associated with seizures. Seizures were the initial sign of stroke in 80 (89%) of 90 cases and …

MaleSubarachnoid hemorrhageComorbidityCentral nervous system diseaseHematomaEmbolusmedicineHumansProspective StudiesRegistriescardiovascular diseasesProspective cohort studyStrokeAgedAged 80 and overEpilepsybusiness.industryVascular diseaseIncidenceCerebral InfarctionIntracranial Embolism and ThrombosisMiddle AgedSubarachnoid HemorrhageIntracranial Arteriosclerosismedicine.diseaseCerebrovascular DisordersNeurologyEmbolismIschemic Attack TransientAnesthesiacardiovascular systemRegression AnalysisFemaleFranceNeurology (clinical)businessEpilepsia
researchProduct

[Italy 2014: 1,000 new cancer cases every day, but mortality is decreasing].

2015

In Italy in 2014 1,000 new cancer cases every day, but mortality is decreasing

MaleSurvival Ratecancer incidenceItalyNeoplasmsHumansFemaleMorbidityMortalitySex Distributioncancer in Italy cancer registriesSettore MED/42 - Igiene Generale E ApplicataEpidemiologia e prevenzione
researchProduct

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national reg…

2021

Introduction: Preoperative treatment and adequate surgery increase local control in rectal cancer. However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included in the Rectal Cancer Registry of the Spanish Associations of Surgeons. Method: This is a STROBE-compliant retrospective analysis of a prospective database. All patients operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006–2009; II)2010–2013; III)2014–2…

MaleSurvivalColorectal cancermedicine.medical_treatmentT stage030230 surgeryTNM0302 clinical medicineRegistriesStage (cooking)Rectal cancerAged 80 and overMargins of ExcisionGeneral MedicineMiddle AgedNeoadjuvant TherapySurvival Ratemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtyNeoadjuvant treatmentPrognosiRectum03 medical and health sciencesYoung AdultmedicineAdjuvant therapyHumansChemotherapyAgedNeoplasm StagingRetrospective StudiesChemotherapyRadiotherapybusiness.industryRectal NeoplasmsCancerChemoradiotherapy Adjuvantmedicine.diseaseSurgeryRadiation therapySpainT-stageSurgerybusinessFollow-Up StudiesForecasting
researchProduct

Five-Year Results of the Bioflow-III Registry:Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent

2018

Abstract Purpose We aimed to assess long-term safety and performance of the Orsiro sirolimus-eluting coronary stent with biodegradable polymer in a large unselected population and in pre-specified subgroups. Methods BIOFLOW-III is a prospective, multicenter, international, observational registry with follow-up visits scheduled at 6 and 12 months, and at 3 and 5 years ( NCT01553526 ). Results 1356 patients with 1738 lesions were enrolled. Of those, 392 (28.9%) declined to participate in the study extension from 18 months to 5 years, 37 (2.7%) withdrew consent, and 89 (6.6%) were lost to follow-up. At 5-years, Kaplan-Meier estimates of target lesion failure, defined as a composite of cardiac …

MaleTarget lesionTime Factorsmedicine.medical_treatmentMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsAbsorbable ImplantsBiodegradable polymerProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionAngioplasty Balloon Coronaryeducation.field_of_studyDiabetesDrug-Eluting StentsGeneral MedicineCoronary artery stenosisMiddle AgedTreatment OutcomeDrug-eluting stentFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyPolyestersPopulationHybrid stentProsthesis Design03 medical and health sciencesDiabetes mellitusCoronary stentmedicineHumanseducationAgedSirolimusbusiness.industryCoronary ThrombosisStentCardiovascular Agentsmedicine.diseaseConfidence intervalSurgeryCoronary OcclusionChronic DiseaseDrug-eluting stentbusiness
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct

Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.

2015

BACKGROUND A retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs). OBJECTIVES The authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs. METHODS Follow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization. RESULTS The mean patient age was 62.0 +/- 10.4 years; 88.5% were men. Procedural and clinical…

MaleTime FactorsIncidenceMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareHospitalsEuropeElectrocardiographyPercutaneous Coronary InterventionPostoperative ComplicationsTreatment OutcomeCoronary Occlusionchronic total occlusionsJ-CTO scoreChronic DiseaseHumansretrograde PCI revascularizationFemaleHospital MortalityProspective StudiesRegistrieschronic total occlusionFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

2020

Objective Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI >= 75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI >= 75 years. Methods We included 979 patients with STEMI >= 75 years, from the ATencion HOspitalaria del Sindrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-P…

MaleTime FactorsPercutaneoussistema de registrosmedicine.medical_treatmenthumanosComorbidityCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regression0302 clinical medicineRecurrenceRisk Factorsevaluación de riesgosST segmentRegistries1506030212 general & internal medicineMyocardial infarctionAged 80 and overancianocoronary intervention (PCI)resultado del tratamientoCardiogenic shockAge FactorsShockstemiTreatment Outcomesurgical procedures operativeCardiologyFemaleAcute coronary syndromeCardiology and Cardiovascular MedicineStemiAcute coronary syndromemedicine.medical_specialtyShock CardiogenicPulmonary EdemaRisk Assessmentacute coronary syndromeedema pulmonar03 medical and health sciencesfactores de tiempoPercutaneous Coronary Interventionchoquecirugía coronaria percutáneaInternal medicinemedicinefactores de riesgoHumanscardiovascular diseasesAgedCoronary intervention (PCI)business.industryPercutaneous coronary interventionmedicine.diseaseSpainPropensity score matchingST Elevation Myocardial InfarctionbusinessrecurrenciaOpen Heart
researchProduct